CD8 + T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing

Nature Communications

Volumn 7, Issue , 2016, Pages

  Schneider Hohendorf, Tilman ^a   Mohan, Hema ^a   Bien, Christian G ^b   Breuer, Johanna ^a   Becker, Albert ^c   Görlich, Dennis ^a   Kuhlmann, Tanja ^a   Widman, Guido ^d   Herich, Sebastian ^a   Elpers, Christiane ^a   Melzer, Nico ^a   Dornmair, Klaus ^e   Kurlemann, Gerhard ^a   Wiendl, Heinz ^a   Schwab, Nicholas ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b EPILEPSY CENTER BETHEL   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; NATALIZUMAB; RITUXIMAB; T LYMPHOCYTE RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ALLELE; ANTIGEN; BLOOD; BRAIN; CELLS AND CELL COMPONENTS; DISEASE SEVERITY; ENCEPHALITIS; NEUROLOGY; PATHOGENICITY;

ADOLESCENT; ADULT; ALLELE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN ATROPHY; BRAIN BIOPSY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; COMMON COLD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEADACHE; HEMISPHERECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MIDDLE AGED; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PATHOGENICITY; PRESCHOOL CHILD; RASMUSSEN SYNDROME; SCHOOL CHILD; SEQUENCE ANALYSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE RECEPTOR SEQUENCING; YOUNG ADULT; CENTRAL NERVOUS SYSTEM; CHEMISTRY; DRUG EFFECTS; ENCEPHALITIS; IMMUNOLOGY; MOLECULAR GENETICS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; ENCEPHALITIS; HUMANS; MOLECULAR SEQUENCE DATA; NATALIZUMAB; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RITUXIMAB; SEQUENCE ANALYSIS, PROTEIN;

EID: 84962748059     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11153     Document Type: Article

References (49)

1. Bien, C. G., Elger, C. E. & Wiendl, H. Advances in pathogenic concepts and therapeutic agents in Rasmussens encephalitis. Expert Opin. Investig. Drugs 11, 981-989 (2002).
2. Rasmussen, T., Olszewski, J. & Lloyd-Smith, D. Focal seizures due to chronic localized encephalitis. Neurology 8, 435-445 (1958).
3. Bien, C. G. et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussens encephalitis. Ann. Neurol. 51, 311-318 (2002).
4. Varadkar, S. et al. Rasmussens encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 13, 195-205 (2014).
5. Andermann, F. & Farrell, K. Early onset Rasmussens syndrome: a malignant, often bilateral form of the disorder. Epilepsy Res. 70(Suppl 1): S259-S262 (2006).
6. Andermann, F. Chronic Encephalitis and Epilepsy: Rasmussens Syndrome. (Butterworth-Heinemann, 1991).
7. Bien, C. G. et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 54, 543-550 (2013).
8. Villani, F. et al. Adult-onset Rasmussens encephalitis: anatomicalelectrographic- clinical features of 7 Italian cases. Epilepsia 47(Suppl 5): 41-46 (2006).
9. Farrell, M. A. et al. Chronic encephalitis associated with epilepsy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 89, 313-321 (1995).
10. Bien, C. G. et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128, 454-471 (2005).
11. Rogers, S. W. et al. Autoantibodies to glutamate receptor GluR3 in Rasmussens encephalitis. Science 265, 648-651 (1994).
12. Wiendl, H. et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussens encephalitis. Neurology 57, 1511-1514 (2001).
13. Watson, R. et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63, 43-50 (2004).
14. Bauer, J. et al. Astrocytes are a specific immunological target in Rasmussens encephalitis. Ann. Neurol. 62, 67-80 (2007).
15. Schwab, N. et al. CD8q T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 132, 1236-1246 (2009).
16. Li, Y. et al. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. J. Immunol. 158, 1428-1437 (1997).
17. Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099-4107 (2009).
18. Robins, H. et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14-19 (2012).
19. Miqueu, P. et al. Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases. Mol. Immunol. 44, 1057-1064 (2007).
20. Bittner, S. et al. Rasmussen encephalitis treated with natalizumab. Neurology 81, 395-397 (2013).
21. Schneider-Hohendorf, T. et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J. Exp. Med. 211, 1833-1846 (2014).
22. Widman, G. et al. Treating a GAD65 antibody-associated limbic encephalitis with basiliximab: a case study. Front. Neurol. 6, 167 (2015).
23. Wilson, E. H., Weninger, W. & Hunter, C. A. Trafficking of immune cells in the central nervous system. J. Clin. Invest. 120, 1368-1379 (2010).
24. Engelhardt, B. & Ransohoff, R. M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 33, 579-589 (2012).
25. Obermeier, B. et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 14, 688-693 (2008).
26. Pannetier, C. et al. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc. Natl Acad. Sci. USA 90, 4319-4323 (1993).
27. Argaet, V. P. et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180, 2335-2340 (1994).
28. Risitano, A. M. et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 364, 355-364 (2004).
29. Robins, H. S. et al. Overlap and effective size of the human CD8β T cell receptor repertoire. Sci. Transl. Med. 2, 47ra64-47ra64 (2010).
30. Rechavi, E. et al. Timely and spatially regulated maturation of B and T cell repertoire during human fetal development. Sci. Transl. Med. 7, 276ra25-276ra25 (2015).
31. Hall, M. A., Reid, J. L. & Lanchbury, J. S. The distribution of human TCR junctional region lengths shifts with age in both CD4 and CD8 T cells. Int. Immunol. 10, 1407-1419 (1998).
32. van den Beemd, R. et al. Flow cytometric analysis of the Vbeta repertoire in healthy controls. Cytometry 40, 336-345 (2000).
33. Gjertsen, H. A., Lundin, K. E., Hansen, T. & Thorsby, E. T cells specific for viral antigens presented by HLA-Dw4 recognize DR13 on allogeneic cells: a possible mechanism for induction of rejection. Transpl. Immunol. 1, 126-131 (1993).
34. Oksenberg, J. R. et al. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68-70 (1993).
35. Owens, G. C. et al. Evidence for the involvement of gamma delta T cells in the immune response in Rasmussen encephalitis. J. Neuroinflammation 12, 134 (2015).
36. Schuster, F. R. et al. Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia. Blood Cancer J. 1, e8 (2011).
37. Venturi, V., Price, D. A., Douek, D. C. & Davenport, M. P. The molecular basis for public T-cell responses? Nat. Rev. Immunol. 8, 231-238 (2008).
38. Junker, A. et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 130, 2789-2799 (2007).
39. Muraro, P. A. et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J. Clin. Invest. 124, 1168-1172 (2014).
40. Mélet, J. et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 65, 2783-2790 (2013).
41. Stüve, O. et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59, 743-747 (2006).
42. Kivisäkk, P. et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72, 1922-1930 (2009).
43. Warnke, C. et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 81, 1400-1408 (2013).
44. Seitz, S. et al. Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc. Natl Acad. Sci. USA 103, 12057-12062 (2006).
45. Mamedov, I. Z. et al. Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling. Front. Immunol. 4, 456 (2013).
46. Carlson C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun 4 2680(2013).
47. Shannon C. E. A mathematical theory of communication. ACM SIGMOBILE Mobile Comput. Commun. Rev 5 3-55(2001).
48. Kirsch, I. R. et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci. Transl. Med. 7, 308ra158-308ra158 (2015).
49. Marrero, I., Hamm, D. E. & Davies, J. D. High-throughput sequencing of isletinfiltrating memory CD4β T cells reveals a similar pattern of TCR Vb usage in prediabetic and diabetic NOD mice. PLoS ONE 8, e76546 (2013).